Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Friday, March 11, 2011

Momentum Magazine - Spring edition




Click the above photo




***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Wednesday, March 9, 2011

International Panel Revises “McDonald Criteria” for Diagnosing MS



Mar 09, 2011

An international panel has revised and simplified the “McDonald Criteria” commonly used to diagnose multiple sclerosis, incorporating new data that should speed the diagnosis without compromising accuracy. The International Panel on Diagnosis of MS, organized and supported by the National MS Society and the European Committee for Treatment and Research in Multiple Sclerosis, was chaired by Chris H. Polman, MD, PhD (Free University of Amsterdam). Full details are available in the free-access paper published in the February 2011 issue of Annals of Neurology (Ann Neurol 2011;69:292-302).
“Treating MS early and effectively is likely our best way to prevent permanent damage to the nervous system, so speeding the diagnosis of MS without compromising accuracy is a key goal,” stated National MS Society Chief Medical Officer Aaron Miller, MD, Professor of Neurology and Medical Director of the MS Center at Mount Sinai Medical Center in New York City. “These updated diagnostic criteria appear to achieve this goal.”
The National MS Society is developing materials to help neurologists understand and apply the 2010 revised diagnostic criteria in practice. These include plans to produce pocket cards summarizing the new criteria. (These will be available from the National MS Society’s Professional Resource Center in coming weeks.) Download a Tipsheet (.pdf) for neurologists that summarizes the new criteria.

>> Read more - directly from The National MS Society


====================
****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

Monday, March 7, 2011

IF in or Around London, HL621 – Get £60 for taking part in an interview about Multiple Sclerosis


Thanks for your interested in our latest research project about MS.  We are carrying out a market research survey among people with multiple sclerosis to understand the treatment choices MS patients are provided with and factors that influence which treatment you receive.
The research will take the form of a 60 minute interview and will take place face to face.  You can either come to central London to be interviewed or we can send an interviewer to your own home so you do not need to travel. 
If you do take part in the interview we will reward you with £60 to thank you for your time and effort.
In this case not all Multiple sclerosis patients will qualify.  You  will need to meet at least the following criteria:-
·         1. Have been diagnosed with multiple sclerosis
·         2. Have or are  being treated with one of the following
   Avonex  / beta interferon 1a
   Betaferon/ Extavia /beta interferon 1b
   Copaxone  / glatiramer acetate
   Rebif /beta interferon 1a
·         3. Be available for an interview between 8th March 2011 and 24th March 2011
·         4. Based in or around London.
If you wish to take part please write to me at belinda.shale@healthcarelandscape.com giving a telephone number where we can contact you.  Please could you put either HL621 London MS  in the subject line for easy reference?
If you know somebody who may be interested please get in touch.
One of my colleagues will give you a call to discuss the research in more detail and to set up a time for your interview.



===================
****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

There’s living with Multiple Sclerosis. And there’s living well with Multiple Sclerosis.


Taking the right medication for you is only part of treating your multiple sclerosis. Dietfitness, stress relief — these things matter to your overall health, too. When done properly, they may make a big difference in helping you live a fuller life with multiple sclerosis.

Live well. Stay active. That’s MS Active Wellness.

We know you have goals and dreams. We want to help you achieve them with healthier, more active living. We’ve partnered with MS experts, patients and nurses to create healthy ideas that inspire, challenge and may ultimately help you. Whether you’re looking to start an exercise routineor whip up a healthy dessert, you’ve come to the right place. Continue to check back regularly; we’re constantly updating the site with new and improved content.

Watch Videos and read more by clicking here


****************************************************************
"Providing You with 'MS Views and News'is what we do"
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  - all contributions are tax deductible -
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************

'MS Views and News' - MS Trial ALERT for glatiramer acetate (Copaxone)



To read from our website, click here


Summary: Investigators worldwide are recruiting 1350 people with MS to study the safety and effectiveness of glatiramer acetate (Teva Pharmaceutical Industries, Ltd.). The current approved dose for glatiramer acetate is 20 mg per day delivered subcutaneously (under the skin), and this study is investigating the effectiveness of a higher dose, 40 mg, given less frequently (three times a week). The one-year study is funded by Teva Pharmaceutical Industries, Ltd., and is also called the GALA study.

Rationale: Glatiramer acetate is a synthetic protein that simulates myelin basic protein, a component of the myelin that insulates nerve fibers in the brain and spinal cord. This therapy seems to block myelin-damaging T-cells through a mechanism that is not completely understood. Glatiramer acetate is approved by the U.S. Food and Drug Administration to reduce the frequency of relapses in patients with relapsing-remitting MS and for use in individuals who have experienced a first clinical episode (clinically-isolated syndrome) and have MRI features that are consistent with MS.

Eligibility and details: Participants should be 18 to 55 years of age with a confirmed diagnosis of relapsing-remitting MS. Participants must be in a relapse-free, stable neurological condition for a minimum of 30 days, but have experienced at least one documented relapse in the past 12 months, two documented relapses in the past 24 months, or one documented relapse between 12 and 24 months with disease activity on MRI. Further details on enrollment criteria are available from the contact below.
Participants will be randomly assigned to receive either glatiramer acetate 40 mg or inactive placebo three times a week subcutaneously for 12 months. The primary endpoint being measured is the effectiveness in reducing the total number of relapses, and secondary endpoints being measured are new disease activity on MRI, cumulative disease activity on MRI, and brain tissue volume loss. Other endpoints under study include quality of life.

Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please emailUStevatrials@teva.co.il.

Sites are going to be recruiting in the following U.S. cities:

Akron, OH 
Aurora, CO
Boulder, CO
Centennial, CO
Columbus, OH
Dayton, OH
Detroit, MI
Fort Collins, CO
Fullerton, CA
Gilbert, AZ
Kirkland, WA
La Jolla, CA
Lenexa, KS
Lexington, KY
Lubbock, TX
Miami, FL
Naples, FL
Nashville, TN
Northbrook, IL
Oklahoma City, OK
Phoenix, AZ
Pompano Beach, FL
Ponte Verde, FL
Richmond, VA
Roanoke, VA
Round Rock, TX
Salt Lake City, UT
San Antonio, TX
Sarasota, FL
Shreveport, LA
Tampa, FL
Uniontown, OH
Vero Beach, FL
Vienna, VA



~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
***************************************************************************************
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************